Concentrations	12 Months Ended
Dec. 31, 2017
Concentrations [Abstract]
Concentrations	18. Concentrations Major Customers Sales to two major customers aggregate to approximately 29% , 41% and 31% of the Company’s net sales for the years ended December 31, 2017, 2016 and 2015, respectively. Net accounts receivable from these customers totaled $0.1 at each of the years ended December 31, 2017 and 2016. Major Suppliers Due to requirements of the U.S. Food and Drug Administration and other factors, the Company is generally unable to make immediate changes to its supplier arrangements. Manufacturing services related to each of the Company’s pharmaceutical products are primarily provided by a single source. The Company’s raw materials are also provided by a single source for each product. Management attempts to mitigate this risk through long‑term contracts and inventory safety stock.

Concentrations

12 Months Ended

Dec. 31, 2017

18. Concentrations

Major Customers

Sales to two major customers aggregate to approximately 29% , 41% and 31% of the Company’s net sales for the years ended December 31, 2017, 2016 and 2015, respectively. Net accounts receivable from these customers totaled $0.1 at each of the years ended December 31, 2017 and 2016.

Major Suppliers

Due to requirements of the U.S. Food and Drug Administration and other factors, the Company is generally unable to make immediate changes to its supplier arrangements. Manufacturing services related to each of the Company’s pharmaceutical products are primarily provided by a single source. The Company’s raw materials are also provided by a single source for each product. Management attempts to mitigate this risk through long‑term contracts and inventory safety stock.